INCY Incyte Corporation

74.18
+0.95  (+1%)
Previous Close 73.23
Open 72.05
Price To Book 6.19
Market Cap 16,080,409,112
Shares 216,775,534
Volume 1,966,333
Short Ratio
Av. Daily Volume 1,923,210
Stock charts supplied by TradingView

NewsSee all news

  1. Incyte Names New Member to Its Board of Directors

    Incyte (NASDAQ:INCY) announces the appointment of Katherine High, M.D., as a new member of the Board of Directors, effective March 25, 2020. "We are delighted to announce that Kathy is joining the Incyte Board of

  2. Data from Phase 3 TRuE-AD Trials of Ruxolitinib Cream in Atopic Dermatitis to be Presented at the 2020 Revolutionizing Atopic Dermatitis Virtual Conference

    Investor conference call and webcast scheduled for Monday, April 6, 2020 at 8:00 a.m. EDT Incyte (NASDAQ:INCY) today announced that data from the Phase 3 TRuE-AD program evaluating ruxolitinib cream for the treatment

  3. Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata

    INDIANAPOLIS, March 16, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy

  4. MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab

    PLANEGG/MUNICH, GERMANY, and WILMINGTON, DE / ACCESSWIRE / March 3, 2020 / MorphoSys AG ((FSE: MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) and Incyte Corporation (NASDAQ:INCY) announced today that their

  5. Incyte Partners with Artist and Patient J.G. Jones to Raise Awareness for Myeloproliferative Neoplasms (MPNs)

    - Incyte announces launch of "Rare Reflections: MPNs Unmasked" as part of its ongoing efforts to raise awareness of MPNs - J.G. Jones, a comic book artist who was diagnosed with an MPN over a decade ago, creates

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 3 BREEZE-AD5 trial met primary endpoint - January 30, 2020.
Baricitinib
Atopic dermatitis
PDUFA date under priority review May 30, 2020.
Pemigatinib (FIGHT-202)
Cholangiocarcinoma
Phase 2 interim data released at ASH 2018.
INCB54828 (FIGHT-203)
MPN (Myeloproliferative Neoplasms)
Phase 2 updated data due 2H 2020.
INCB54828 Pemigatinib (FIGHT-201)
Bladder cancer
Phase 1/2 initiated April 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-207)
Solid tumors
Phase 1/2 various presentations at ASCO June 5, 2017. Updated data at ESMO Saturday, 9 September 2017 showed ORR 56% in melanoma patients.
Epacadostat with Keytruda - ECHO-202/KEYNOTE-037
NSCLC, RCC, Triple-Negative Breast, Ovarian, Urothelial Carcinoma, Solid Tumors
Phase 1/2 trial enrolling. Oral presentation at ASCO June 5, 2017.
Epacadostat with Opdivo (nivolumab) - (ECHO-204)
Solid tumors
Phase 1/2 enrolling.
Epacadostat with Keytruda - (ECHO-206)
Cancer - solid tumors
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line non-small cell lung cancer
Phase 3 trial planned for 2017.
Epacadostat with Opdivo (nivolumab)
First-line head and neck cancer
Approved November 16, 2011.
Jakafi
Myelofibrosis
Phase 3 trial did not meet primary endpoint - January 2, 2020.
Itacitinib - GRAVITAS-301
Treatment-naïve acute GVHD
Phase 2 trial to be discontinued - noted June 21, 2018.
INCB50465 (CITADEL-202)
Diffuse large B cell lymphoma
Recruitment has been discontinued - February 13, 2020.
Ruxolitinib (RESET)
Essential thrombocythemia
Phase 3 final data due 3Q 2020.
Ruxolitinib - REACH 3
Steroid-refractory chronic GVHD (Graft versus host disease)
Phase 3 data met primary endpoint - October 16, 2019.
Ruxolitinib - REACH 2
Steroid-refractory acute GVHD (Graft versus host disease)
Phase 3 planned.
Epacadostat with Keytruda
Squamous cell carcinoma of the head and neck cancer
Phase 3 planned.
Epacadostat with Keytruda
Bladder cancer
Phase 3 planned.
Epacadostat with Keytruda
Non-small cell lung cancer (NSCLC)
CRL received April 14, 2017. NDA resubmitted. Approval announced for low dose only - June 1, 2018.
Baricitinib
Rheumatoid arthritis
Phase 3 trial did not meet primary endpoint - noted April 6, 2018.
Epacadostat with Keytruda - ECHO-301
Cancer - first-line metastatic melanoma.
Approved December 4, 2014.
Jakafi (ruxolitinib) (RESPONSE)
Polycythemia Vera
FDA approval announced May 24, 2019.
Ruxolitinib
Graft versus host disease
Phase 3 trial discontinued due to lack of efficacy
Ruxolitinib - JANUS 1 and JANUS 2
Cancer - Pancreatic
Phase 2 trial stopped January 2016 due to lack of efficacy
Ruxolitinib
Colorectal cancer
Endpoint not met, mid-2014
Jakafi (ruxolitinib) (RELIEF)
Disease-related symptoms in patients with Polycythemia Vera
Phase 3 trial to commence 1H 2018.
Epacadostat with durvalumab
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-303)
Bladder cancer
PDUFA date under priority review announced February 11, 2020. PDUFA date not announced but estimated August 11, 2020 based on a 6-month timeline.
Capmatinib
Non-small cell lung cancer
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-307)
Bladder cancer
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-304)
Head & neck cancer
Phase 3 enrollment to be discontinued.
Epacadostat with nivolumab (ECHO-309)
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with nivolumab (ECHO-310)
Head and neck cancer
Phase 3 trial to be converted into randomized Phase 2 trial.
Epacadostat with pembrolizumab (ECHO-306)
Non-small cell lung cancer (NSCLC)
Phase 3 trial to be converted into randomized Phase 2 trial.
Epacadostat with pembrolizumab (ECHO-305)
Non-small cell lung cancer (NSCLC)
Phase 3 enrollment to be discontinued.
Epacadostat with pembrolizumab (ECHO-302)
Renal cancer
Phase 1 oral abstract June 1, 2018, 2:45p.m. CT. Abstract 8005.
Ruxolitinib, Lenalidomide, and Methylprednisolone
Relapsed/Refractory Multiple Myeloma
Phase 1/2 ongoing.
INCB024360 + Epacadostat
Solid tumors
Phase 3 primary endpoint met - February 19, 2020.
Ruxolitinib - TRuE-AD1
Atopic dermatitis
Phase 2 initial data due 2020.
Parsaclisib INCB50465 (CITADEL-203)
Follicular lymphoma
Phase 2 initial data due 2020.
Parsaclisib INCB50465 (CITADEL-204)
Marginal zone lymphoma
Phase 2 initial data due 2020.
Parsaclisib INCB50465 (CITADEL-205)
Mantle cell lymphoma
Phase 2 data due 2H 2020.
INCMGA0012
Anal cancer
Phase 2 data presented at ASH December 2, 2018.
INCB50465 and ruxolitinib
Myelofibrosis
Phase 3 initial data due in 2021.
Ruxolitinib - TRuE-V
Vitiligo
Phase 1/2 data at ESMO 2019 noted - 7% PR rate.
INCB001158
Solid tumors
Phase 3 data due 2020.
Baricitinib
Alopecia Areata
Phase 3 data due 2021.
Baricitinib
Systemic lupus erythematosus (SLE)
Phase 3 data due 2021.
Itacitinib - GRAVITAS-309
Chronic Graft-Versus-Host Disease
Phase 3 initiation of dosing announced June 4, 2019.
Pemigatinib (FIGHT-302)
Cholangiocarcinoma - first line

Latest News

  1. Incyte Names New Member to Its Board of Directors

    Incyte (NASDAQ:INCY) announces the appointment of Katherine High, M.D., as a new member of the Board of Directors, effective March 25, 2020. "We are delighted to announce that Kathy is joining the Incyte Board of

  2. Data from Phase 3 TRuE-AD Trials of Ruxolitinib Cream in Atopic Dermatitis to be Presented at the 2020 Revolutionizing Atopic Dermatitis Virtual Conference

    Investor conference call and webcast scheduled for Monday, April 6, 2020 at 8:00 a.m. EDT Incyte (NASDAQ:INCY) today announced that data from the Phase 3 TRuE-AD program evaluating ruxolitinib cream for the treatment

  3. Lilly Receives FDA Breakthrough Therapy Designation for Baricitinib for the Treatment of Alopecia Areata

    INDIANAPOLIS, March 16, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy

  4. MorphoSys and Incyte Announce Antitrust Clearance of Global Collaboration and License Agreement for Tafasitamab

    PLANEGG/MUNICH, GERMANY, and WILMINGTON, DE / ACCESSWIRE / March 3, 2020 / MorphoSys AG ((FSE: MOR, Prime Standard Segment, MDAX &, TecDAX, NASDAQ:MOR) and Incyte Corporation (NASDAQ:INCY) announced today that their

  5. Incyte Partners with Artist and Patient J.G. Jones to Raise Awareness for Myeloproliferative Neoplasms (MPNs)

    - Incyte announces launch of "Rare Reflections: MPNs Unmasked" as part of its ongoing efforts to raise awareness of MPNs - J.G. Jones, a comic book artist who was diagnosed with an MPN over a decade ago, creates

  6. Incyte Announces Launch of the Incyte Ingenuity Award Program to Recognize Innovation Within the GVHD Community

    Up to $100,000 to be awarded for an innovative solution addressing an unmet need in the graft-versus-host disease (GVHD) community Visit www.IncyteIngenuityAward.com to apply now! Incyte (NASDAQ:INCY) is proud to

  7. Incyte Announces Positive Topline Results From Phase 3 TRuE-AD Program Evaluating Ruxolitinib Cream in Patients With Atopic Dermatitis

    Primary and secondary endpoints met in both TRuE-AD1 and TRuE-AD2 Incyte (NASDAQ:INCY) today announced that the second randomized, vehicle-controlled, pivotal Phase 3 study from the TRuE-AD clinical trial program has

  8. Incyte Reports 2019 Fourth Quarter and Year-End Financial Results and Provides 2020 Financial Guidance and Updates on Key Clinical Programs

    Total product and royalty revenues of $579 million (+24%) in 4Q 2019 and $2.1 billion (+22%) for the full year 2019; Jakafi® (ruxolitinib) revenues of $466 million (+23%) in 4Q 2019 and $1.7 billion (+21%) for the full

  9. Incyte to Present at Upcoming Investor Conference

    Incyte (NASDAQ:INCY) announced today that it will present at the Cowen and Company 40th Annual Health Care Conference on Monday, March 2, 2020 at 11:20 a.m. ET in Boston. The presentation will be webcast live and can

  10. Incyte Announces Acceptance and Priority Review of NDA for Capmatinib for Advanced Non-Small Cell Lung Cancer

    The U.S. Food and Drug Administration (FDA) Priority Review for capmatinib is based on Phase 2 data in first-line and previously treated patients with MET exon 14 skipping (METex14) mutated advanced non-small cell lung

  11. Lilly and Incyte Announce Positive Top-Line Results from the North American (BREEZE-AD5) Phase 3 Study of Oral Selective JAK Inhibitor Baricitinib in Patients with Moderate to Severe Atopic Dermatitis

    INDIANAPOLIS, Jan. 30, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD5, an investigational Phase 3, randomized,

  12. Incyte Announces that the TRuE-AD2 Pivotal Trial of Ruxolitinib Cream Met its Primary Endpoint in Patients with Atopic Dermatitis

    Incyte (NASDAQ:INCY) today announced positive topline results from its randomized, vehicle-controlled, pivotal Phase 3 TRuE-AD2 study evaluating the safety and efficacy of ruxolitinib cream in adolescent and adult

  13. Lilly and Incyte Announce Top-Line Results from Phase 3 Study (BREEZE-AD4) of Oral Selective JAK Inhibitor Baricitinib in Combination with Topical Corticosteroids in Patients with Moderate to Severe Atopic Dermatitis Not Controlled with Cyclosporine

    INDIANAPOLIS, Jan. 24, 2020 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD4, an investigational Phase 3, randomized,

  14. Incyte to Report Fourth Quarter and Year-End Financial Results

    Incyte (NASDAQ:INCY) announced today that it has scheduled its fourth quarter and year-end 2019 financial results conference call and webcast for 8:00 a.m. ET on Thursday, February 13, 2020. The schedule for the press

  15. MorphoSys and Incyte Sign Global Collaboration and License Agreement for Tafasitamab

    - MorphoSys and Incyte to co-commercialize tafasitamab in the U.S.- Incyte has exclusive commercialization rights outside of the U.S.- MorphoSys and Incyte to host joint conference call on January 13, 2020 at 7:00am PST

  16. Incyte Announces the Validation by the European Medicines Agency of its Marketing Authorization Application for Pemigatinib in Patients with Cholangiocarcinoma

    Incyte (NASDAQ:INCY) today announced the validation of the Company's Marketing Authorization Application (MAA) for pemigatinib for the treatment of adults with locally advanced or metastatic

  17. Incyte Announces Results of Phase 3 Study of Itacitinib in Patients with Treatment-Naïve Acute Graft-Versus-Host Disease

    - GRAVITAS-301 results show that treatment with itacitinib in combination with corticosteroids did not statistically improve overall response rate or non-relapse mortality compared to placebo plus corticosteroids -

  18. Incyte Names New Member to Its Board of Directors

    Incyte (NASDAQ:INCY) announces the appointment of Edmund P. Harrigan, M.D., as a new member of the Board of Directors, effective December 16, 2019. "We are delighted to welcome Edmund to Incyte. His extensive

  19. Incyte to Present at Upcoming Investor Conference

    Incyte Corporation (NASDAQ:INCY) announced today that it will present at the J. P. Morgan 38th Annual Healthcare Conference on Monday, January 13, 2020 at 8:30 am (PST) in San Francisco. The presentation will be

  20. Incyte Announces Acceptance and Priority Review of NDA for Pemigatinib as a Treatment for Patients with Cholangiocarcinoma

    Incyte (NASDAQ:INCY) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review its New Drug Application (NDA) for pemigatinib, a selective fibroblast growth factor receptor (FGFR)

  21. Data from Incyte's Oncology Portfolio Accepted for Presentation at the 61st Annual ASH Meeting

    Incyte (NASDAQ:INCY) announces that numerous abstracts, including data from its clinical development programs for ruxolitinib (Jakafi®), itacitinib and ponatinib (Iclusig®) will be presented at the upcoming American

  22. Incyte to Present at Upcoming Investor Conference

    Incyte Corporation (NASDAQ:INCY) announced today that it will present at the Piper Jaffray 31st Annual Healthcare Conference on Wednesday, December 4, 2019 at 8:30 am (EST) in New York. The presentation will be

  23. Incyte Reports 2019 Third Quarter Financial Results and Provides Updates on Key Clinical Programs

    Total product and royalty revenues of $534 million (+24% vs. Q3 2018) and Jakafi® (ruxolitinib) revenues of $433 million (+25% vs. Q3 2018) for the quarter ended September 30, 2019; raising full year 2019 Jakafi

  24. Incyte to Present at Upcoming Investor Conference

    Incyte Corporation (NASDAQ:INCY) announced today that it will present at the Credit Suisse 28th Annual Healthcare Conference on Tuesday, November 12, 2019 at 8:35 am (MST) / 10:35 am (EST) in Scottsdale, Arizona. The

  25. Incyte Announces Positive 52-Week Results From a Randomized Phase 2 Study of Ruxolitinib Cream in Patients With Vitiligo

    - Data presented at EADV demonstrate continued improvement in repigmentation of vitiligo lesions upon longer treatment duration with ruxolitinib cream Incyte (NASDAQ:INCY) today announces positive 52-week results from

  26. Lilly to Unveil New Data for the Treatments of Complex Dermatological Conditions at the 28th Annual European Academy of Dermatology and Venereology (EADV) Congress

    INDIANAPOLIS, Oct. 8, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) announced today that it will present new data for Taltz® (ixekizumab), Olumiant® (baricitinib) and mirikizumab at the 28th annual European

  27. Incyte Announces Positive Updated Results from Phase 2 Trial of Pemigatinib in Patients with Previously Treated, Advanced Cholangiocarcinoma

    Data presented at ESMO support the planned submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for pemigatinib before the end of 2019 Investor conference call and webcast

  28. Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo

    Incyte (NASDAQ:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult

  29. Incyte Announces First Patient Treated in Phase 3 Clinical Trial Program Evaluating Ruxolitinib Cream in Patients with Vitiligo

    Incyte (NASDAQ:INCY) today announced that the first patient has been treated in the Phase 3 TRuE-V clinical trial program evaluating the safety and efficacy of ruxolitinib cream as a monotherapy for adolescent and adult

  30. Incyte to Host Investor Conference Call from ESMO 2019

    Incyte (NASDAQ:INCY) announced today that it will host a conference call and webcast Friday, September 27, 2019, at 11:00 a.m. EDT (5:00 p.m. CEST), to discuss updated pemigatinib data presented at the European Society

  31. BriaCell to Present September 19th at 2nd Annual Next Gen Immuno-Oncology Congress in Philadelphia

    BERKELEY, Calif., Sept. 16, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  32. BriaCell Announces Closing of Upsized Non-Brokered Private Placement of $846,301.49

    BERKELEY, Calif. and VANCOUVER, British Columbia, Sept. 09, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  33. Incyte Launches #MyMPNChallenge to Inspire the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month

    Social media campaign designed to spark MPN conversations and increase awareness and education about MPNs, a group of rare, chronic blood cancers, launches today To further support the MPN community, for every

  34. Incyte Launches #MyMPNChallenge to Inspire the Myeloproliferative Neoplasm (MPN) Community During Blood Cancer Awareness Month

    Social media campaign designed to spark MPN conversations and increase awareness and education about MPNs, a group of rare, chronic blood cancers, launches today To further support the MPN community, for every

  35. Data from Incyte's Oncology Portfolio to be Featured at the 2019 ESMO Congress

    Updated Phase 2 results from the FIGHT-202 study highlight the potential of pemigatinib as a treatment option for patients with previously treated, advanced cholangiocarcinoma Incyte (NASDAQ:INCY) announces that

  36. BriaCell Announces Participation at the 21st Annual Global Investment Conference in New York City September 8-10, 2019

    BERKELEY, Calif. and VANCOUVER, British Columbia, Aug. 27, 2019 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp.

  37. Lilly Announces Top-Line Phase 3 Results for Oral JAK Inhibitor Baricitinib, in Combination with Topical Corticosteroids in Adult Patients with Moderate to Severe Atopic Dermatitis

    INDIANAPOLIS, Aug. 23, 2019 /PRNewswire/ -- Eli Lilly and Company (NYSE:LLY) and Incyte Corporation (NASDAQ:INCY) announced today that baricitinib met the primary endpoint in BREEZE-AD7, the third pivotal Phase 3 trial

  38. Incyte to Present at Upcoming Investor Conferences

    Incyte Corporation (NASDAQ:INCY) announced today that it will present at the following investor conferences during the month of September: Morgan Stanley 17th Annual Global Healthcare Conference on Tuesday, September